168 related articles for article (PubMed ID: 12592021)
1. Backbone dynamics of the human MIA protein studied by (15)N NMR relaxation: implications for extended interactions of SH3 domains.
Stoll R; Renner C; Buettner R; Voelter W; Bosserhoff AK; Holak TA
Protein Sci; 2003 Mar; 12(3):510-9. PubMed ID: 12592021
[TBL] [Abstract][Full Text] [Related]
2. The extracellular human melanoma inhibitory activity (MIA) protein adopts an SH3 domain-like fold.
Stoll R; Renner C; Zweckstetter M; Brüggert M; Ambrosius D; Palme S; Engh RA; Golob M; Breibach I; Buettner R; Voelter W; Holak TA; Bosserhoff AK
EMBO J; 2001 Feb; 20(3):340-9. PubMed ID: 11157741
[TBL] [Abstract][Full Text] [Related]
3. Extracellular SH3 domain containing proteins--features of a new protein family.
Stoll R; Bosserhoff A
Curr Protein Pept Sci; 2008 Jun; 9(3):221-6. PubMed ID: 18537677
[TBL] [Abstract][Full Text] [Related]
4. NMR-based Drug Development and Improvement Against Malignant Melanoma - Implications for the MIA Protein Family.
Arnolds O; Zhong X; Tuo Yip K; Schöpel M; Kohl B; Pütz S; Abdel-Jalil R; Stoll R
Curr Med Chem; 2017; 24(17):1788-1796. PubMed ID: 28595551
[TBL] [Abstract][Full Text] [Related]
5. Solution structure and dynamics of melanoma inhibitory activity protein.
Lougheed JC; Domaille PJ; Handel TM
J Biomol NMR; 2002 Mar; 22(3):211-23. PubMed ID: 11991352
[TBL] [Abstract][Full Text] [Related]
6. Expression, function and clinical relevance of MIA (melanoma inhibitory activity).
Bosserhoff AK; Buettner R
Histol Histopathol; 2002 Jan; 17(1):289-300. PubMed ID: 11813878
[TBL] [Abstract][Full Text] [Related]
7. Structure of melanoma inhibitory activity protein, a member of a recently identified family of secreted proteins.
Lougheed JC; Holton JM; Alber T; Bazan JF; Handel TM
Proc Natl Acad Sci U S A; 2001 May; 98(10):5515-20. PubMed ID: 11331761
[TBL] [Abstract][Full Text] [Related]
8. Detailed analysis of MIA protein by mutagenesis.
Stoll R; Lodermeyer S; Bosserhoff AK
Biol Chem; 2006 Dec; 387(12):1601-6. PubMed ID: 17132106
[TBL] [Abstract][Full Text] [Related]
9. Backbone dynamics of homologous fibronectin type III cell adhesion domains from fibronectin and tenascin.
Carr PA; Erickson HP; Palmer AG
Structure; 1997 Jul; 5(7):949-59. PubMed ID: 9261088
[TBL] [Abstract][Full Text] [Related]
10. Cloning of a novel malignant melanoma-derived growth-regulatory protein, MIA.
Blesch A; Bosserhoff AK; Apfel R; Behl C; Hessdoerfer B; Schmitt A; Jachimczak P; Lottspeich F; Buettner R; Bogdahn U
Cancer Res; 1994 Nov; 54(21):5695-701. PubMed ID: 7923218
[TBL] [Abstract][Full Text] [Related]
11. Detection of melanoma cells in the blood of melanoma patients by melanoma-inhibitory activity (MIA) reverse transcription-PCR.
Mühlbauer M; Langenbach N; Stolz W; Hein R; Landthaler M; Buettner R; Bosserhoff AK
Clin Cancer Res; 1999 May; 5(5):1099-105. PubMed ID: 10353744
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of p66shc by melanoma inhibitory activity.
Kasuno K; Naqvi A; Dericco J; Yamamori T; Santhanam L; Mattagajasingh I; Yang S; Meyskens FL; Bosserhoff AK; Irani K
Cell Death Differ; 2007 Aug; 14(8):1414-21. PubMed ID: 17431427
[TBL] [Abstract][Full Text] [Related]
13. [MIA ("melanoma inhibitory activity"). Biological functions and clinical relevance in malignant melanoma].
Bosserhoff AK; Golob M; Buettner R; Landthaler M; Hein R
Hautarzt; 1998 Oct; 49(10):762-9. PubMed ID: 9857251
[TBL] [Abstract][Full Text] [Related]
14. Mouse CD-RAP/MIA gene: structure, chromosomal localization, and expression in cartilage and chondrosarcoma.
Bosserhoff AK; Kondo S; Moser M; Dietz UH; Copeland NG; Gilbert DJ; Jenkins NA; Buettner R; Sandell LJ
Dev Dyn; 1997 Apr; 208(4):516-25. PubMed ID: 9097023
[TBL] [Abstract][Full Text] [Related]
15. Novel mechanism of regulation of the non-receptor protein tyrosine kinase Csk: insights from NMR mapping studies and site-directed mutagenesis.
Shekhtman A; Ghose R; Wang D; Cole PA; Cowburn D
J Mol Biol; 2001 Nov; 314(1):129-38. PubMed ID: 11724538
[TBL] [Abstract][Full Text] [Related]
16. The role of backbone motions in ligand binding to the c-Src SH3 domain.
Wang C; Pawley NH; Nicholson LK
J Mol Biol; 2001 Nov; 313(4):873-87. PubMed ID: 11697910
[TBL] [Abstract][Full Text] [Related]
17. Active detachment involves inhibition of cell-matrix contacts of malignant melanoma cells by secretion of melanoma inhibitory activity.
Bosserhoff AK; Stoll R; Sleeman JP; Bataille F; Buettner R; Holak TA
Lab Invest; 2003 Nov; 83(11):1583-94. PubMed ID: 14615412
[TBL] [Abstract][Full Text] [Related]
18. Solution structure of the C-terminal SH2 domain of the p85 alpha regulatory subunit of phosphoinositide 3-kinase.
Siegal G; Davis B; Kristensen SM; Sankar A; Linacre J; Stein RC; Panayotou G; Waterfield MD; Driscoll PC
J Mol Biol; 1998 Feb; 276(2):461-78. PubMed ID: 9512716
[TBL] [Abstract][Full Text] [Related]
19. RT loop flexibility enhances the specificity of Src family SH3 domains for HIV-1 Nef.
Arold S; O'Brien R; Franken P; Strub MP; Hoh F; Dumas C; Ladbury JE
Biochemistry; 1998 Oct; 37(42):14683-91. PubMed ID: 9778343
[TBL] [Abstract][Full Text] [Related]
20. Solution structure of the second SH3 domain of human CMS and a newly identified binding site at the C-terminus of c-Cbl.
Yao B; Zhang J; Dai H; Sun J; Jiao Y; Tang Y; Wu J; Shi Y
Biochim Biophys Acta; 2007 Jan; 1774(1):35-43. PubMed ID: 17188587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
